Race Oncology Ltd (ASX:RAC, OTC:RAONF) announced the completion of the first phase of its board renewal process. The transition phase saw the departure of non-executive chair Mary Harney and non-executive director Phil Lynch, with Dr. Pete Smith and Dr. Daniel Tillett stepping into executive chair and CEO/MD roles, respectively. Newly appointed independent non-executive director Dr. Serge Scrofani will bring his 28 years of healthcare sector experience to the company, which is focused on commercialising its cardioprotective cancer therapies. Dr. Scrofani previously led strategic initiatives at CSL and now runs a strategic advisory firm, Poplar Advisory. The company aims to leverage his expertise to advance its innovative therapies.
Biotechnology, Healthcare,Australia, United States
https://mergersacquisitions.einnews.com/article/740042800/qdno6MeSMiEulSY8?ref=rss&ecode=Q1vNcweEggLWKz7L